OncoMatch/Clinical Trials/NCT07504458
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Is NCT07504458 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including QTX-2101 + ATRA and IV arsenic trioxide (ATO) + ATRA for acute promyelocytic leukemia (apl).
Treatment: QTX-2101 + ATRA · IV arsenic trioxide (ATO) + ATRA — This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: RARA PML-RARA fusion
confirmed diagnosis of APL proven by standard genetic testing (t(15;17) or PML-RARA)
Demographics
Lab requirements
Cardiac function
no significant heart rhythm problems including long qt syndrome, serious arrhythmias, very slow heart rate, or prolonged qtc on ecg
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Quetzal Site 1 · Duarte, California
- Quetzal Site 2 · The Bronx, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07504458 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require RARA?
Yes, RARA PML-RARA fusion is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 71 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages